UBS Raises Tenet Healthcare Price Target to $288, Reaffirms "Buy" Rating

UBS recently re-affirmed its "Buy" rating for Tenet Healthcare (THC), signaling continued confidence in the company's performance. The investment bank significantly increased its price target for THC to $288, up from the previous $260. This positive adjustment aligns with generally optimistic sentiment from several other market analysts. However, GuruFocus's GF Value estimates a potential downside for THC, suggesting a divergence in valuation perspectives. The upward revision by UBS reflects strong optimism regarding Tenet Healthcare's future prospects, despite the presence of varied valuations.